id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-310631-ru5f69qg	Joachim, Denner	SARS-CoV-2 and enhancing antibodies	2020-05-07		.txt	text/plain	567	40	50	In contrast, other CoV infections including the severe acute respiratory syndrome (SARS), the Middle East respiratory syndrome (MERS) and the recent COVID-19 are characterised by a higher pathogenicity in certain human populations and may be lethal. In persons infected by SARS-CoV enhancing antibodies and neutralising antibodies may partly counteract each other's function. In the case, cross-reactive enhancing antibodies exist, the infection with the new SARS-CoV-2 may be enhanced by these pre-existing antibodies against common CoV. Common CoV circulate every year in the human population [1] and it sounds logical that the amount of anti-CoV antibodies including potentially enhancing antibodies is higher in older persons. The assumption of ADE with pre-existing enhancing antibodies against common CoV may also explain why in some regions the infection rate with SARS-CoV-2 and its pathogenicity is higher compared with other regions. The possible existence of enhancing antibodies is also of importance for the development of a vaccine against SARS-CoV-2.	./cache/cord-310631-ru5f69qg.txt	./txt/cord-310631-ru5f69qg.txt